Pharma channel feed – Endpoints News

Pharma channel feed

Gushing red ink, biotech billionaire Soon-Shiong slashes staff at NantHealth by 300, sells assets

8 years ago

UK’s Biotecnol strikes a deal with CRUK to move new immuno-oncology drug into PhI

8 years ago

Eyeing an IPO, Sutro retools its $1B I/O deal with Celgene but stays focused on BCMA

8 years ago

Spurred by Gottlieb, FDA on track to the most generic drug OKs ever in 1 year

8 years ago

Roche sells off its struggling IL-13 drug lebrikizumab in $1.4B Dermira deal

8 years ago

Prepping for PhIII cancer study, Sellas reverse merges its way to a public listing

8 years ago

Look out Gilead, AbbVie’s hep C combo comes with stellar data, 8-week regimen and a killer price

8 years ago

Dynavax shares dip after FDA asks for more time to sort out Heplisav post-marketing plan

8 years ago

Trump will sign FDA user fee reauthorization bill, ending threat of agency layoffs

8 years ago

Bristol-Myers beefs up big cancer drug pipeline, buying IFM drugs in $2.3B-plus deal

8 years ago

10 years and $100M-plus later, GSK shutters a China R&D site during a major pipeline overhaul

8 years ago

Sanofi shifts focus to internal R&D as it preps an end to a stunningly effective Regeneron alliance

8 years ago

FDA offers another speedy cancer drug OK, approving Jazz’s Vyxeos for acute myeloid leukemia

8 years ago

Top FDA official accused CDER chief Woodcock of appearing biased, browbeating reviewers in demanding eteplirsen OK

8 years ago

FDA experts turn thumbs down on J&J’s troubled rheumatoid arthritis drug sirukumab

8 years ago

After a $200M financing, Highland Therapeutics falls silent on ADHD drug’s fate as PDUFA sails by

8 years ago

Running out of cash and kicked out of its HQ by the landlord, PixarBio hunkers down and slashes staff

8 years ago

Updated: Celgene, Agios win a landmark FDA OK for new AML drug Idhifa

8 years ago

Despite blockbuster boasts for R&D work, pressure increases on Pfizer to do a megadeal

8 years ago

Indivior gets a speedy review for opioid addiction drug as FDA vows to fight a crisis

8 years ago

Looking for an oncology reboot, Sanofi, Regeneron shoot for a fast and flashy FDA OK of a promising new PD-1

8 years ago

FDA slams J&J’s blockbuster contender sirukumab on ‘important safety risks’

8 years ago

Kite shoots for first CAR-T OK in Europe, staying one step behind Novartis in US race

8 years ago

Bristol-Myers, Clovis leap into PhIII combo studies in a PD-1/PARP play as rivals circle

8 years ago

First page Previous page 317 318 319320321 322 323 Next page Last page